antipyrine has been researched along with Diabetes Mellitus, Type 2 in 16 studies
Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29)
antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with edaravone (3 and 10 mg/kg) significantly diminished the cerebral infarct, oedema volume and improved functional recovery of neurological deficits." | 5.38 | Edaravone offers neuroprotection in a diabetic stroke model via inhibition of endoplasmic reticulum stress. ( Sharma, SS; Srinivasan, K, 2012) |
| "The antipyrine test was used to reflect the liver mixed function oxidase system." | 2.66 | Glucose tolerance and insulin response to glucose load before and after enzyme inducing therapy in subjects with glucose intolerance and patients with NIDDM having hyperinsulinemia or relative insulin deficiency. ( Karvonen, I; Sotaniemi, EA, 1989) |
| "Type 2 diabetes mellitus is a vast growing progressive disease that almost affects one person among every twelve globally." | 1.42 | Novel 4-heteroaryl-antipyrines as DPP-IV inhibitors. ( Abdulla, MM; Badrey, MG; Eldebss, TM; Gomha, SM; Mayhoub, AS, 2015) |
| "Treatment with edaravone (3 and 10 mg/kg) significantly diminished the cerebral infarct, oedema volume and improved functional recovery of neurological deficits." | 1.38 | Edaravone offers neuroprotection in a diabetic stroke model via inhibition of endoplasmic reticulum stress. ( Sharma, SS; Srinivasan, K, 2012) |
| "Antipyrine elimination was studied in 11 type I and 10 type II diabetic patients and 2 age-matched control groups." | 1.28 | Differential effect of type I and type II diabetes mellitus on antipyrine elimination. ( Adithan, C; Bapna, JS; Chandrasekar, S; Danda, D; Shashindran, CH; Swaminathan, RP, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (37.50) | 18.7374 |
| 1990's | 2 (12.50) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 4 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Terzioğlu, K | 1 |
| Ediger, D | 1 |
| Tülümen Öztürk, R | 1 |
| Durmuş, E | 1 |
| Alışır, MF | 1 |
| Gomha, SM | 1 |
| Eldebss, TM | 1 |
| Badrey, MG | 1 |
| Abdulla, MM | 1 |
| Mayhoub, AS | 1 |
| Luo, G | 1 |
| He, J | 1 |
| Wu, T | 1 |
| Huang, Y | 1 |
| Miao, Z | 1 |
| Zhao, Z | 1 |
| Wang, X | 1 |
| Wang, Y | 1 |
| Srinivasan, K | 1 |
| Sharma, SS | 1 |
| Hayashi, T | 1 |
| Mori, T | 1 |
| Sohmiya, K | 1 |
| Okada, Y | 1 |
| Inamoto, S | 1 |
| Okuda, N | 1 |
| Mori, H | 1 |
| Kitaura, Y | 1 |
| Sotaniemi, EA | 5 |
| Stengård, JH | 1 |
| Saarni, HU | 1 |
| Arranto, AJ | 2 |
| Keinänen, K | 1 |
| Kerola, T | 1 |
| Sutinen, S | 1 |
| Pirttiaho, HI | 1 |
| Salmela, PI | 1 |
| Pelkonen, RO | 1 |
| Pitkänen, U | 1 |
| Luoma, PV | 1 |
| Klebovich, I | 1 |
| Rautio, A | 2 |
| Salonpää, P | 1 |
| Arvela, P | 1 |
| Pelkonen, O | 2 |
| Matzke, GR | 1 |
| Frye, RF | 1 |
| Early, JJ | 1 |
| Straka, RJ | 1 |
| Carson, SW | 1 |
| Vannucci, SJ | 1 |
| Willing, LB | 1 |
| Goto, S | 1 |
| Alkayed, NJ | 1 |
| Brucklacher, RM | 1 |
| Wood, TL | 1 |
| Towfighi, J | 1 |
| Hurn, PD | 1 |
| Simpson, IA | 1 |
| Tapanainen, P | 1 |
| Pasanen, M | 1 |
| Shobha, JC | 1 |
| Raghuram, TC | 1 |
| Kumar, AD | 1 |
| Krishnaswamy, K | 1 |
| Adithan, C | 1 |
| Danda, D | 1 |
| Shashindran, CH | 1 |
| Bapna, JS | 1 |
| Swaminathan, RP | 1 |
| Chandrasekar, S | 1 |
| Karvonen, I | 1 |
| Zysset, T | 1 |
| Wietholtz, H | 1 |
| Korhonen, T | 1 |
| Uusitupa, M | 1 |
| Voutilainen, E | 1 |
| Sarlund, H | 1 |
| Laakso, M | 1 |
| Laitinen, M | 1 |
| Silvasti, M | 1 |
| Pyörälä, K | 1 |
5 trials available for antipyrine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Antipyrine, coumarin and glipizide affect n-acetylation measured by caffeine test.
Topics: Acetylation; Adult; Analysis of Variance; Antipyrine; Caffeine; Coumarins; Diabetes Mellitus, Type 2 | 1995 |
Evaluation of the influence of diabetes mellitus on antipyrine metabolism and CYP1A2 and CYP2D6 activity.
Topics: Acetylation; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Antitussive Agents; Caffein | 2000 |
Diabetes and elimination of antipyrine in man: an analysis of 298 patients classified by type of diabetes, age, sex, duration of disease and liver involvement.
Topics: Adolescent; Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Blood Glu | 2002 |
Glucose tolerance and insulin response to glucose load before and after enzyme inducing therapy in subjects with glucose intolerance and patients with NIDDM having hyperinsulinemia or relative insulin deficiency.
Topics: Adult; Antipyrine; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Diet, Diabetic; Female; Gluc | 1989 |
Lack of effect of hepatic enzyme induction on metabolic control in patients with type 2 (non-insulin-dependent) diabetes.
Topics: Adult; Aged; Antipyrine; Diabetes Mellitus, Type 2; Double-Blind Method; Enzyme Induction; Female; G | 1987 |
11 other studies available for antipyrine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Kounis syndrome not induced but prevented by the implantation of a drug-eluting stent: a case report.
Topics: Acetaminophen; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Diabetes Mellitus, Type 2; | 2017 |
Novel 4-heteroaryl-antipyrines as DPP-IV inhibitors.
Topics: Animals; Antipyrine; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Pe | 2015 |
The Therapeutic Effect of Stellate Ganglion Block on Facial Nerve Palsy in Patients with Type 2 Diabetes Mellitus.
Topics: Adult; Anesthetics, Local; Antipyrine; Aspirin; Autonomic Nerve Block; Blood Glucose; Dexamethasone; | 2015 |
Edaravone offers neuroprotection in a diabetic stroke model via inhibition of endoplasmic reticulum stress.
Topics: Animals; Antipyrine; Apoptosis; Caspase 12; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type | 2012 |
Efficacy of edaravone, a free radical scavenger, on left ventricular function and structure in diabetes mellitus.
Topics: Animals; Antioxidants; Antipyrine; Blood Glucose; Blotting, Western; Diabetes Mellitus, Type 2; Edar | 2003 |
Hepatic glucose-6-phosphatase activity in non-insulin dependent diabetics. Effect of enzyme-inducing drugs.
Topics: Aged; Antipyrine; Blood Glucose; Chlorpropamide; Diabetes Mellitus, Type 2; Enzyme Induction; Female | 1984 |
Drug metabolism in diabetic subjects with fatty livers.
Topics: Adult; Aged; Antipyrine; Cytochrome P-450 Enzyme System; Diabetes Mellitus, Type 2; Fatty Liver; Fem | 1984 |
Experimental stroke in the female diabetic, db/db, mouse.
Topics: Animals; Antipyrine; Autoradiography; Brain; Carbon Radioisotopes; Cerebral Infarction; Cerebrovascu | 2001 |
Antipyrine kinetics in undernourished diabetics.
Topics: Adult; Anthropometry; Antipyrine; Blood Glucose; Diabetes Mellitus, Type 2; Half-Life; Humans; India | 1991 |
Differential effect of type I and type II diabetes mellitus on antipyrine elimination.
Topics: Adolescent; Adult; Antipyrine; Blood Glucose; Chromatography, High Pressure Liquid; Diabetes Mellitu | 1989 |
Differential effect of type I and type II diabetes on antipyrine disposition in man.
Topics: Adult; Aged; Aged, 80 and over; Antipyrine; Biotransformation; Diabetes Mellitus, Type 1; Diabetes M | 1988 |